Published September 2015
| public
Journal Article
Protein degradation: Prime time for PROTACs
- Creators
-
Deshaies, Raymond J.
Chicago
An error occurred while generating the citation.
Abstract
PROTACs are heterobifunctional small molecules that simultaneously bind a target protein and a ubiquitin ligase, enabling ubiquitination and degradation of the target. Major progress in developing potent and specific PROTACs has recently been reported, invigorating prospects for novel PROTAC-based therapies.
Additional Information
© 2015 Macmillan Publishers Limited. Published online 18 August 2015. R.J.D. is co-founder of a company (Cleave Biosciences) that is developing therapeutics based on targeting enzymes in the ubiquitin-proteasome pathway. R.J.D. also holds stock in Cleave Biosciences and serves as a consultant and member of their Scientific Advisory Board.Additional details
- Eprint ID
- 60179
- DOI
- 10.1038/nchembio.1887
- Resolver ID
- CaltechAUTHORS:20150911-085528272
- Created
-
2015-09-11Created from EPrint's datestamp field
- Updated
-
2021-11-10Created from EPrint's last_modified field